Invention Grant
US08815297B2 Modulation of beta 2 adrenergic receptors by inhibitors of EGLN3 or pVHL
有权
通过EGLN3或pVHL抑制剂调节β2肾上腺素能受体
- Patent Title: Modulation of beta 2 adrenergic receptors by inhibitors of EGLN3 or pVHL
- Patent Title (中): 通过EGLN3或pVHL抑制剂调节β2肾上腺素能受体
-
Application No.: US13256954Application Date: 2010-03-31
-
Publication No.: US08815297B2Publication Date: 2014-08-26
- Inventor: Jonathan S. Stamler , Liang Xie
- Applicant: Jonathan S. Stamler , Liang Xie
- Applicant Address: US NC Durham
- Assignee: Duke University
- Current Assignee: Duke University
- Current Assignee Address: US NC Durham
- Agency: Bacon & Thomas, PLLC
- International Application: PCT/US2010/000956 WO 20100331
- International Announcement: WO2010/117423 WO 20101014
- Main IPC: A61K35/14
- IPC: A61K35/14
Abstract:
This present invention relates to methods, compositions, and kits useful for treating a patient having or at risk for developing a disorder associated with decreased expression of β2 adrenergic receptors or need for increased 132 adrenergic receptor activity.
Public/Granted literature
- US20120121720A1 Modulation of Beta 2 Adrenergic Receptors by Inhibitors of EGLN3 or pVHL Public/Granted day:2012-05-17
Information query
IPC分类:
